BIO Seeks Weight-Of-Evidence Standard For Drug Approvals
Drug reviewers should be able to consider efficacy evidence beyond double-blind, randomized controlled trials, the group says in proposals to stimulate biomedical innovation.
Drug reviewers should be able to consider efficacy evidence beyond double-blind, randomized controlled trials, the group says in proposals to stimulate biomedical innovation.